Findings

What do systematic reviews say?

32 questions · 32 findings · 16 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 28.1%GRADE not reported 0 · 0%Very low 2 · 6.3%Low 7 · 21.9%Moderate 6 · 18.8%High 8 · 25%

Balneotherapy vs no treatment

Health‐related quality of life –CIVIQ2 Scale: 20–100 · people with chronic venous insufficiency

1 finding from 1 review

Balneotherapy for chronic venous insufficiency 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 153 participants
Very low

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2791 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Mepolizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1285 participants
Moderate

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Mucolytic vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD

1 finding from 1 review

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2721 participants
Moderate

Cognitive‐behavioural intervention vs controls

Health‐related quality of life end of treatment (0‐80 scale) Higher scores indicate lower health‐related quality of life · patients with fibromyalgia

1 finding from 1 review

Cognitive behavioural therapies for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 1238 participants
Low

Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo

Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) · patients with fibromyalgia

Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported health‐related quality of life (0‐100 scale) Higher… compared with placebo (low certainty).

1 finding from 1 review

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia 2018 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6861 participants
Low

Information or education intervention vs no education

Health‐related quality of life (HRQoL) · adult ICU patients and their carers

1 finding from 1 review

Information or education interventions for adult intensive care unit (ICU) patients and their carers 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 143 participants
Very low

ICU follow‐up services vs standard care or no follow‐up service

Health‐related quality of life (HRQoL) · adult survivors of the ICU, excluding those already in an existing follow‐up or rehabilitation programme

1 finding from 1 review

Follow‐up services for improving long‐term outcomes in intensive care unit (ICU) survivors 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 286 participants
Low

Pursed lip breathing vs no breathing exercises

Health‐related quality of life Dyspnoea domain of Hiratsuka scale Scores range from 0 to 100, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Breathing exercises for chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 60 participants
Low